Aceto’s expansion roll continues with buyout of Irish biopharma manufacturernews2021-10-13T18:12:04+00:00October 13th, 2021|Fierce Pharma|
Moderna criticized for COVID-19 vaccine strategy putting once feel-good success story in jeopardynews2021-10-13T14:58:41+00:00October 13th, 2021|Fierce Pharma|
Johnson & Johnson, Moderna COVID-19 vaccines work as intended, FDA staff say ahead of high-stakes booster meetingnews2021-10-13T14:40:28+00:00October 13th, 2021|Fierce Pharma|
ECTRIMS: Roche touts 8-year Ocrevus data to defend multiple sclerosis leadershipnews2021-10-13T14:11:27+00:00October 13th, 2021|Fierce Pharma|
Ardelyx axes 65% of workforce with no clarity from FDA on kidney drug’s futurenews2021-10-13T13:36:12+00:00October 13th, 2021|Fierce Pharma|
FDA Form 483 puts a wrinkle into Revance’s application for Botox rivalnews2021-10-13T13:31:52+00:00October 13th, 2021|Fierce Pharma|
Bristol Myers Squibb engaged in Acceleron buyout talks but couldn’t justify the price: reportnews2021-10-13T13:10:53+00:00October 13th, 2021|Fierce Pharma|
Olympian joins Eli Lilly to level the field for health inequity in breast cancernews2021-10-13T12:00:50+00:00October 13th, 2021|Fierce Pharma|
Eli Lilly’s Verzenio snags first-in-class FDA approval for early breast cancer. But limited label poses a challengenews2021-10-13T09:56:32+00:00October 13th, 2021|Fierce Pharma|
Pharma saw huge reputation gains in the last year. It should make sure not to squander them, expert saysnews2021-10-12T18:56:11+00:00October 12th, 2021|Fierce Pharma|
